S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila

Journal of Neuroscience Research

Volumn 85, Issue 6, 2007, Pages 1271-1278

  Steinhilb, Michelle L ^a,c   Dias Santagata, Dora ^a   Mulkearns, Erin E ^a   Shulman, Joshua M ^a   Biernat, Jacek ^b   Mandelkow, Eva Maria ^b   Feany, Mel B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

^c CENTRAL MICHIGAN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Kinase; Neurodegeneration; Phosphorylation; Tauopathy

Indexed keywords

ALANINE; CYCLIN DEPENDENT KINASE 5; PHOSPHATASE; PHOSPHOTRANSFERASE; PROLINE; PROLINE DIRECTED PROTEIN KINASE; PROTEIN P35; SERINE; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; THREONINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DROSOPHILA; IN VIVO STUDY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALANINE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DROSOPHILA; DROSOPHILA PROTEINS; ENZYME ACTIVATION; EYE; MICROSCOPY, ELECTRON, SCANNING; MUTATION; NEUROTOXICITY SYNDROMES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROLINE-DIRECTED PROTEIN KINASES; PROTEIN KINASES; TAU PROTEINS;

EID: 34248219026     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21232     Document Type: Article

References (46)

1. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD. 2000. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 97:2910-2915.
2. Bian F, Nath R, Sobocinski G, Booher RN, Lipinski WJ, Callahan MJ, Pack A, Wang KK, Walker LC. 2002. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 446:257-266.
3. Biernat J, Mandelkow EM. 1999. The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol Biol Cell 10:727-740.
4. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. 1993. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11:153-163.
5. Boutros M, Paricio N, Strutt DI, Mlodzik M. 1998. Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling. Cell 94:109-118.
6. Braak H, Braak E. 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259.
7. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. 2000. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95-130.
8. Carmel G, Mager EM, Binder LI, Kuret J. 1996. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 271:32789-32795.
9. Connell-Crowley L, Le Gall M, Vo DJ, Giniger E. 2000. The cyclin-dependent kinase Cdk5 controls multiple aspects of axon patterning in vivo. Curr Biol 10:599-602.
10. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. 2003. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40:471-483.
11. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. 1995. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285-298: discussion 298-304.
12. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. 1998. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 143:777-794.
13. Feany MB, Dickson DW. 1996. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 40:139-148.
14. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. 2005. Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 112:813-838.
15. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:4913-4917.
16. Hannus M, Feiguin F, Heisenberg CP, Eaton S. 2002. Planar cell polarization requires Widerborst, a B′ regulatory subunit of protein phosphatase 2A. Development 129:3493-3503.
17. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM. 1998. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914-1917.
18. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basini H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. 1998. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705.
19. Hyman BT, Van Hocsen GW, Wolozin BL, Davies P, Kromer LJ, Damasio AR. 1988. Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann Neurol 23:371-379.
20. Ihara Y, Nukina N, Miura R, Ogawara M. 1986. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem (Tokyo) 99:1807-1810.
21. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH. 2002. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34:509-519.
22. Jicha GA, Berenfeld B, Davies P. 1999a. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res 55:713-723.
23. Jicha GA, Bowser R, Kazam IG, Davies P. 1997. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48:128-132.
24. Jicha GA, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J, Davies P. 1999b. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci 19:7486-7494.
25. Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB. 2006. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 16:230-241.
26. Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Gotz J. 2001. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 276:38193-38200.
27. Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM. 2006. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 103:9673-9678.
28. Lee VM, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
29. Li W, Ohlmeyer JT, Lane ME, Kalderon D. 1995. Function of protein kinase A in hedgehog signal transduction and Drosophila imaginal disc development. Cell 80:553-562.
30. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. 2001. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20:27-39.
31. Ma E, Haddad G. 1999. A Drosophila CDK5alpha-like molecule and its possible role in response to 0(2) deprivation. Biochem Biophys Res Commun 261:459-463.
32. Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. 2004. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol 167:99-110.
33. Nishimura I, Yang Y, Lu B. 2004. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116:671-682.
34. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. 2005. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102:6990-6995.
35. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijaman M, Lau LF, Duff K. 2003. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38:555-565.
36. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. 1998. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43:815-825.
37. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. 1999. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38:3549-3558.
38. Seitz A, Kojima H, Oiwa K, Mandelkow EM, Song YH, Mandelkow E. 2002. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J 21:4896-4905.
39. Shulman JM, Feany MB. 2003. Genetic modifiers of tauopathy in Drosophila. Genetics 165:1233-1242.
40. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. 1996. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 17:1201-1207.
41. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. 1998. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 95:7737-7741.
42. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F. 2000. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275:41340-41349.
43. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. 2002. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051-1063.
44. Vincent I, Rosado M, Davies P. 1996. Mitotic mechanisms in Alzheimer's disease? J Cell Biol 132:413-425.
45. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. 2001. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293:711-714.
46. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E. 1998. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical- filament-like conformation. Eur J Biochem 252:542-552.